Novel therapeutic Approaches in the treatment of Multiple Myeloma

Last Modified: April 7, 2002

Share article


Conference Dates: Friday, June 21, 2002
Conference Location: Fairchild Auditorium, Stanford Hospital and Clinics, 291 Campus Drive West, Stanford, California, USA


Sponsoring Group: Multiple Myeloma Research Foundation

Who Should Attend: Professionals: hematologists, oncologists, internists, oncology nurses. Patients and families

Topics Covered:

  • transplantation
  • pathogenesis
  • thalidomide
  • biphosphonates
  • novel therapies

Conference Objectives: Education about the latest treatment for Multiple Myeloma

Conference Agenda: Features Dr Stockerl-Goldstein, Dr Martin, Dr Hussein, Dr Roodman, Dr Richardson

Registration Information: For Professionals: Kari Costa, ph 650-724-2708, kcosta@stanford.edu

For Patients: Tammy Smith, ph 203-972-1250, smitht@themmrf.org

Conference Fees: Professionals: MD $75, RN $50, Patients Free

Continuing Education: Yes


News
ASH: Novel Drug Beneficial in Multiple Myeloma

Jul 26, 2014 - In patients with relapsed or resistant multiple myeloma who have received up to three prior therapies excluding the first-generation proteasome inhibitor bortezomib, treatment with the second-generation proteasome inhibitor carfilzomib is associated a high response rate and a low incidence of side effects, according to research presented at the annual meeting of the American Society of Hematology, held from Dec. 5 to 8 in New Orleans.



I Wish You Knew

How cancer patients have changed my life

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More